GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » Shiller PE Ratio

Moberg Pharma AB (Moberg Pharma AB) Shiller PE Ratio : (As of May. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Moberg Pharma AB Shiller PE Ratio Historical Data

The historical data trend for Moberg Pharma AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Shiller PE Ratio Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.81 1.19 0.54 0.49

Moberg Pharma AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.62 0.20 0.21 0.49

Competitive Comparison of Moberg Pharma AB's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Shiller PE Ratio falls into.



Moberg Pharma AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Moberg Pharma AB's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Moberg Pharma AB's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.022/130.9575*130.9575
=-0.022

Current CPI (Dec. 2023) = 130.9575.

Moberg Pharma AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.003 100.541 -0.004
201403 0.047 99.788 0.062
201406 0.044 100.432 0.057
201409 0.038 100.161 0.050
201412 -0.003 100.225 -0.004
201503 0.078 99.950 0.102
201506 0.041 99.995 0.054
201509 0.064 100.228 0.084
201512 0.000 100.276 0.000
201603 -0.042 100.751 -0.055
201606 0.209 101.019 0.271
201609 0.092 101.138 0.119
201612 -0.019 102.022 -0.024
201703 -0.017 102.022 -0.022
201706 -0.046 102.752 -0.059
201709 0.078 103.279 0.099
201712 0.058 103.793 0.073
201803 0.013 103.962 0.016
201806 0.027 104.875 0.034
201809 0.012 105.679 0.015
201812 0.062 105.912 0.077
201903 3.040 105.886 3.760
201906 -0.056 106.742 -0.069
201909 0.160 107.214 0.195
202003 -0.016 106.563 -0.020
202006 0.000 107.498 0.000
202009 -0.025 107.635 -0.030
202012 -0.041 108.296 -0.050
202103 0.000 108.360 0.000
202106 0.000 108.928 0.000
202109 0.000 110.338 0.000
202112 0.000 112.486 0.000
202203 -0.070 114.825 -0.080
202206 -0.041 118.384 -0.045
202209 -0.039 122.296 -0.042
202212 -0.022 126.365 -0.023
202303 -0.032 127.042 -0.033
202306 -0.024 129.407 -0.024
202309 -0.032 130.224 -0.032
202312 -0.022 130.958 -0.022

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Moberg Pharma AB  (OTCPK:MBGPF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Moberg Pharma AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB (Moberg Pharma AB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.